Diabetes Research and Clinical Practice
Volume 77, Issue 3 , Pages 351-356 , September 2007

Oral pioglitazone administration increases food intake through ghrelin-independent pathway in Zucker fatty rat

Received 17 May 2006 ,Revised 11 October 2006 ,Accepted 10 January 2007.

References 

  1. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995;269:543–546
  2. Phillips MS, Liu Q, Hammond HA, Dugan V, Hey PJ, Caskey CJ, et al. Leptin receptor missense mutation in the fatty Zucker rat. Nat. Genet. 1996;13:18–19
  3. Couillard C, Mauriege P, Imbeault P, Prud’homme D, Nadeau A, Tremblay A, et al. Hyperleptmemia is more closely associated with adipose cell hypertrophy than with adipose tissue Hyperplasia. Int. J. Obes. Relat. Metab. Disord. 2000;24:782–788
  4. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–660
  5. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, et al. Ghrelin is anappetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology. 2001;120:337–345
  6. Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem. Biophys. Res. Commun. 2000;276:905–908
  7. Shiiya T, Nakazato M, Mizuta M, Date Y, Mndal MS, Tanaka M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J. Clin. Endocrinol. Metab. 2002;87:240–244
  8. Tamas LH, Sabrina D, Peter S, Mark H, Matthias T. Minireview: Ghrelin and the regulation of energy balance-A hypothalamic perspective. Endocrinology. 2001;142:4163–4169
  9. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation. 2001;104:1430–1435
  10. Toshinai K, Mondal MS, Nakazato M, Date Y, Murakami N, Kojima M, et al. Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem. Biophys. Res. Commun. 2001;281:1220–1225
  11. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407:908–913
  12. Burkey BF, Dong M, Gagen K, Eckhardt M, Dragonas N, Chen W, et al. Pioglitazone promotes energy storage and not expenditure in brown dipose tissue of obese fa/fa Zucker rats: comparison with CL316, 243. Metabolism. 2000;49:1301–1308
  13. Wang Q, Dryden S, Frankish HM, Bing C, Pickavance L, Hopkins D, et al. Increased feeding in fatty Zucker rats by the thaizoli-dindione BRL 49653 (rosiglitazone) and the possible involnement of leptin and hypothalamic neuropeptide Y. Br. J. Pharm. 1997;122:1405–1410
  14. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 1998;101:1354–1361
  15. Hallakou S, Doare L, Foufelle F, Kergoat M, Guerre-Millo M, Berthault MF, et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes. 1997;46:1393–1399
  16. Kelly IE, Walsh K, Han TS, Lean MEJ. Effects of a thiazolidinedione compound on body fat and fat distribution on patients with type 2 diabetes. Diab. Care. 1999;22:288–293
  17. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, et al. Effects of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2002;87:2784–2791
  18. Weir BJ. Mew methods for calculating metabolic rate with special reference to protein metabolism. J. Physiol. 1949;109:1–9
  19. Allison DB, Paultre F, Maggio C, Mezzitis N, Pi-Sunyer FX. The use of areas under curves in diabetes research. Diab. Care. 1995;18:245–250
  20. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPAR γ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094–2099
  21. Masuzaki H, Ogawa Y, Isse N, Satoh N, Okazaki T, Shigemoto M, et al. Human obese gene expression. Adipocyte-specific expression and regional differences in the adipose tissue. Diabetes. 1995;44:855–858
  22. de Souza CJ, Eckhardt M, Gagen K, Dong M, Chen W, Laurent D, et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes. 2001;50:1863–1871
  23. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes. 2001;50:2540–2547
  24. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, et al. A role foGhrelin in the central regulation of feeding. Nature. 2001;409:194–198
  25. Hosoda H, Kojima M, Matsuo H, Kangawa K. Ghrelin and des-acyl ghrelin. Two major forms of rat ghrelin peptide in gastrointestimal tissue. Biochem. Biophys. Res. Commuun. 2000;279:909–913
  26. Akamizu T, Shinomiya T, Irako T, Fukunaga M, Nakai Y, Nakai Y, et al. Separate measurement of plasma levels of acylated and desacyl ghrelin in healthy subjects using a new direct ELISA assay. J. Clin. Endocrinol. Metab. 2005;90:6–9
  27. Tschop M, Smiley D, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407:908–913
  28. Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe Megumi, Miyanaga F, Takaya K, et al. Ghrelin, an endogeneous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes. 2001;50:227–232
  29. Lee HM, Wang G, Englander EW, Kojima M, George H, Greeley J, et al. Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion, enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology. 2002;143:185–190
  30. Pontiroli AE, Lanzi R, Monti LD, Pozza G. Effect of acipimox, a lipid lowering drug, on growth hormone (GH) response to GH-releasing hormone in normal subjects. J. Endocrinol. Invest. 1990;13:539–542
  31. Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Yajima N, et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diab. Care. 1999;22:908–912
  32. Kelly IE, Walsh K, Han TS, Lean MEJ. Effect of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diab. Care. 1999;22:288–293
  33. Ananda B, Michael DJ, Frances MC, Debabrata M, Michael JJ, Robert AR. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diab. Care. 1999;22:288–293
  34. Foellmi-Adams LA, Wyse BM, Herron D, Nedergaard J, Kletzien RF. Induction of uncoupling protein in brown adipose tissue. Biochem. Pharmacol. 1996;52:693–701
  35. Paulik MA, Lenhard JM. Thiazolidindiones inhibit alkaline phosphate activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10Tl/2cells. Cell Tissue Res. 1997;290:79–87
  36. Digby JE, Montague CT, Sewter CP. Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes. Diabetes. 1998;47:138–141
  37. Tai TA, Jennermann C, Brown KK, Oliver BB, MacGinnitie MA, Wilkison WO, et al. Activation of the nuclear receptor peroxisome proliferator-activated receptor γ promotes brown adipocyte differentiation. J. Biol. Chem. 1996;271:29909–29914
  38. Aubert J, Champigny O, Saint-Marc P, Negrel R, Collins S, Ricquir D, et al. Up-regulation of UCP-2 gene expression by PPAR agonist in preadipose and adipose cells. Biochem. Biophys. Res. Commun. 1997;238:606–611

PII: S0168-8227(07)00053-8

doi: 10.1016/j.diabres.2007.01.016

Diabetes Research and Clinical Practice
Volume 77, Issue 3 , Pages 351-356 , September 2007

Article Tools

* Image Usage & Resolution